Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1540 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-24

Study Completion Date

2020-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK

NCT03696407

Advanced Renal Cell Carcinoma

COMPLETED

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

NCT03647878

Advanced Renal Cell Carcinoma Metastatic Renal Cell Carcinoma

ACTIVE_NOT_RECRUITING

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

NCT03419572

Renal Cell Carcinoma

COMPLETED

A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

NCT05361434

Advanced Renal Cell Carcinoma

ACTIVE_NOT_RECRUITING

"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

NCT03538717

Carcinoma, Renal Cell

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subgroup 1

Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.

Cabozantinib

Intervention Type DRUG

oral therapy

Subgroup 2

Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.

Axitinib

Intervention Type DRUG

oral therapy

Subgroup 3

Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)

Cabozantinib

Intervention Type DRUG

oral therapy

Subgroup 4

Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)

Axitinib

Intervention Type DRUG

oral therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cabozantinib

oral therapy

Intervention Type DRUG

Axitinib

oral therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with initial renal cancer diagnosis
* Patients diagnosed at Stage III or Stage IV (as defined in CAS): as evidence for advanced/metastatic RCC
* For patients with Stage I/II or patients with missing information on Staging
* Patients who received SACT1 treatment following initial renal cancer diagnosis through end of enrolment (31 July 2019)
* Patients who received cabozantinib or axitinib treatment

Exclusion Criteria

* Diagnosis of concomitant tumour apart from non-melanoma skin cancer in the three years prior to the diagnosis of aRCC
* Less than 18 years of age at the time of initial aRCC diagnosis
* SACT treatment more than 30 days prior to initial aRCC diagnosis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No